| 초록 |
Background: Accumulating evidence suggests that Th17 immune responses have an important role in the clinical outcome in kidney transplantation. However, currently used immune suppressant, tacrolimus (Tac) cannot effectively suppress this responses. The aim of this study is to investigate whether 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) could regulate Th17 allo-immune responses which is not suppressed by Tacrolimus.
Methods: First, T cell subset including Th1, Th2, Th17 and Treg cells were quantitatively determined upon T-cell- specific stimulation in peripheral blood mononuclear cells (PBMCs) from healthy individuals or kidney transplant recipients (KTRs) under clinically relevant concentrations of 1,25(OH)2D3 or Tac. Second, we investigated the suppressive effect of 1,25(OH)2D3 on interleukin-17 (IL-17) or TNF-α induced inflammatory cytokine secretion from human primary tubular epithelial cells. Third, we investigated the association between 25-hydroxyvitamin D (25(OH)D) level and Th17 associated cytokine level in those patients.
Results: Tac suppressed Treg cells in a concentration-dependent manner, but did not suppress Th17 cells even at high concentration. In contrast, addition of 1,25(OH)2D significantly suppressed Th17 related allo-responses which was not regulated by tacrolimus. In vitro study using HPRTEC, interleukin-17 (IL-17) and tumor necrosis factor-alpha (TNF- α) significantly induce the secretion of inflammatory cytokine, IL-6 and IL-8, however, addition of 1,25(OH)2D significantly reduces the secretion of those cytokines. In renal transplant recipients with stable allograft function, 1,25(OH) 2D level was significantly inversely correlated with IL-17 level. In another group, 25(OH)D level at transplantation was significantly associated with the development of acute rejection within 3 months from KT.
Conclusion: This study suggests that addition of 1,25(OH)2D3 to Tac effectively regulate Th17 alloimmune
responses,
the high level of (25(OH)D is associated with low Th17 associated cytokine level in KTRs. The use of 1,25(OH)2D3 could be proposed as therapeutic strategy to improve allograft outcome. |